Large drugmakers cheapest against their own PE history
Where today's PE sits among every trading day of the company's last ten years: 0 is its cheapest day, 100 its dearest. As of .
- Ranked
- 17
- of 411 large drugmakers we cover
- Median
- 41st pct
- Lowest
- 0th pct
- ANIP
- Range
- 0th pct to 100th pct
median 41st pct
0th pct100th pct
| # | Company | PE vs its 10 years | PE | Its 10y median PE | Market cap |
|---|---|---|---|---|---|
| 1 | ANIPANI Pharmaceuticals | 0th pct | 15.0× | 57.5× | $1.6B |
| 2 | NATRNatures Sunshine Products | 5th pct | 11.9× | 20.2× | $211.5M |
| 3 | BMYBristol-Myers Squibb | 12th pct | 14.0× | 19.9× | $128.7B |
| 4 | JAZZJazz Pharmaceuticals | 16th pct | 14.7× | 20.1× | $13.9B |
| 5 | PAHCPhibro Animal Health | 19th pct | 15.9× | 21.5× | $1.6B |
| 6 | AMPHAmphastar Pharmaceuticals | 31st pct | 15.9× | 20.5× | $1.1B |
| 7 | LFVNLifevantage | 31st pct | 14.7× | 19.4× | $73.5M |
| 8 | PBHPrestige Consumer Healthcare | 32nd pct | 13.9× | 15.3× | $2.4B |
| 9 | LGNDLigand Pharmaceuticals | 41st pct | 32.7× | 37.6× | $6.1B |
| 10 | LLYEli Lilly and | 55th pct | 46.5× | 41.6× | $1.3T |
| 11 | ABBVAbbVie | 74th pct | 49.8× | 27.9× | $511.6B |
| 12 | AMGNAmgen | 80th pct | 29.0× | 21.2× | $252.3B |
| 13 | JNJJohnson & Johnson | 90th pct | 40.9× | 24.3× | $650.2B |
| 14 | CORTCorcept Therapeutics | 93rd pct | 192× | 28.3× | $8.7B |
| 15 | PFEPfizer | 98th pct | 40.6× | 15.8× | $176B |
| 16 | BIIBBiogen | 99th pct | 44.3× | 16.2× | $37B |
| 17 | MRKMerck | 100th pct | 150× | 25.0× | $359.5B |
Not ranked: 326 with no PE (losses over the last year), 15 with under ten years of history. 53 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.
PE vs its 10 years for other groups
Other rankings of large drugmakers
- Large drugmakers with the lowest PE ratio
- Large drugmakers with the lowest price to sales ratio
- Large drugmakers with the lowest EV/EBIT
- Large drugmakers with the highest free cash flow yield
- Large drugmakers with the fastest revenue growth
- Large drugmakers with the fastest earnings growth
- Large drugmakers with the highest profit margins